Statins inhibit expression of Thioredoxin reductase 1 in rat and human liver and reduce tumour development

Biochemical and Biophysical Research Communications

Volumn 417, Issue 3, 2012, Pages 1046-1051

  Skogastierna, Cristine ^a   Johansson, Maria ^a   Parini, Paolo ^a   Eriksson, Mats ^a   Eriksson, Lennart C ^a   Ekström, Lena ^a   Björkhem Bergman, Linda ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Carcinogenesis; HMG CoA reductase inhibitors; Liver; Liver cancer; Liver tissue; Statins; Thioredoxin reductase 1; Thioredoxin reductase 2

Indexed keywords

ATORVASTATIN; COMPLEMENTARY DNA; FLUINDOSTATIN; LATHOSTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; MEVINOLIN; PLACEBO; RNA; THIOREDOXIN REDUCTASE 1; THIOREDOXIN REDUCTASE 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CHOLESTEROL LIVER LEVEL; CONTROLLED STUDY; DRUG MEGADOSE; ENZYME ACTIVITY; GENE EXPRESSION REGULATION; HUMAN; HUMAN TISSUE; LIPID LIVER LEVEL; LIVER; LIVER BIOPSY; LIVER CANCER; LIVER CARCINOGENESIS; LOW DRUG DOSE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; RANDOMIZED CONTROLLED TRIAL; RAT; REAL TIME POLYMERASE CHAIN REACTION;

ANIMALS; ANTICARCINOGENIC AGENTS; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIVER; LIVER NEOPLASMS; MALE; RATS; RATS, INBRED F344; RNA, MESSENGER; THIOREDOXIN REDUCTASE 1; TUMOR CELLS, CULTURED;

RATTUS;

EID: 84856009814     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.12.091     Document Type: Article

References (29)

1. Wilt T.J., Bloomfield H.E., MacDonald R., Nelson D., Rutks I., Ho M., Larsen G., McCall A., Pineros S., Sales A. Effectiveness of statin therapy in adults with coronary heart disease. Arch. Intern. Med. 2004, 164:1427-1436.
2. Bjorkhem-Bergman L., Acimovic J., Torndal U.B., Parini P., Eriksson L.C. Lovastatin prevents carcinogenesis in a rat model for liver cancer. Effects of ubiquinone supplementation. Anticancer Res. 2010, 30:1105-1112.
3. Khurana V., Bejjanki H.R., Caldito G., Owens M.W. Statins reduce the risk of lung cancer in humans: a large case-control study of US veterans. Chest 2007, 131:1282-1288.
4. Poynter J.N., Gruber S.B., Higgins P.D., Almog R., Bonner J.D., Rennert H.S., Low M., Greenson J.K., Rennert G. Statins and the risk of colorectal cancer. N. Engl. J. Med. 2005, 352:2184-2192.
5. Tamura T., Stadtman T.C. A new selenoprotein from human lung adenocarcinoma cells: purification, properties, and thioredoxin reductase activity. Proc. Natl. Acad. Sci. USA 1996, 93:1006-1011.
6. Zhong L., Arner E.S., Ljung J., Aslund F., Holmgren A. Rat and calf thioredoxin reductase are homologous to glutathione reductase with a carboxyl-terminal elongation containing a conserved catalytically active penultimate selenocysteine residue. J. Biol. Chem. 1998, 273:8581-8591.
7. Arner E.S., Holmgren A. Physiological functions of thioredoxin and thioredoxin reductase. Eur. J. Biochem. 2000, 267:6102-6109.
8. Arner E.S., Holmgren A. The thioredoxin system in cancer. Semin. Cancer Biol. 2006, 16:420-426.
9. Bjorkhem L., Teclebrhan H., Kesen E., Olsson J.M., Eriksson L.C., Bjornstedt M. Increased levels of cytosolic thioredoxin reductase activity and mRNA in rat liver nodules. J. Hepatol. 2001, 35:259-264.
10. Parini P., Gustafsson U., Davis M.A., Larsson L., Einarsson C., Wilson M., Rudling M., Tomoda H., Omura S., Sahlin S., Angelin B., Rudel L.L., Eriksson M. Cholesterol synthesis inhibition elicits an integrated molecular response in human livers including decreased ACAT2. Arterioscler. Thromb. Vasc. Biol. 2008, 28:1200-1206.
11. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001, 25:402-408.
12. Inman S.R., Stowe N.T., Cressman M.D., Brouhard B.H., Nally J.V., Satoh S., Satodate R., Vidt D.G. Lovastatin preserves renal function in experimental diabetes. Am. J. Med. Sci. 1999, 317:215-221.
13. Tatsuta M., Iishi H., Baba M., Iseki K., Yano H., Uehara H., Yamamoto R., Nakaizumi A. Suppression by pravastatin, an inhibitor of p21ras isoprenylation, of hepatocarcinogenesis induced by N-nitrosomorpholine in Sprague-Dawley rats. Br. J. Cancer 1998, 77:581-587.
14. Solt D.B., Farber E. New principle for the analysis of chemical carcinogenesis. Nature 1976, 263:702-703.
15. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951, 193:265-275.
16. Acimovic J., Lovgren-Sandblom A., Monostory K., Rozman D., Golicnik M., Lutjohann D., Bjorkhem I. Combined gas chromatographic/mass spectrometric analysis of cholesterol precursors and plant sterols in cultured cells. J. Chromatogr. B 2009, 877:2081-2086.
17. Lund E., Sisfontes L., Reihner E., Bjorkhem I. Determination of serum levels of unesterified lathosterol by isotope dilution-mass spectrometry. Scand. J. Clin. Lab. Invest. 1989, 49:165-171.
18. Graf H., Jungst C., Straub G., Dogan S., Hoffmann R.T., Jakobs T., Reiser M., Waggershauser T., Helmberger T., Walter A., Walli A., Seidel D., Goke B., Jungst D. Chemoembolization combined with pravastatin improves survival in patients with hepatocellular carcinoma. Digestion 2008, 78:34-38.
19. Kawata S., Yamasaki E., Nagase T., Inui Y., Ito N., Matsuda Y., Inada M., Tamura S., Noda S., Imai Y., Matsuzawa Y. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br. J. Cancer 2001, 84:886-891.
20. Yoo M.H., Xu X.M., Carlson B.A., Gladyshev V.N., Hatfield D.L. Thioredoxin reductase 1 deficiency reverses tumor phenotype and tumorigenicity of lung carcinoma cells. J. Biol. Chem. 2006, 281:13005-13008.
21. Cadenas C., Franckenstein D., Schmidt M., Gehrmann M., Hermes M., Geppert B., Schormann W., Maccoux L.J., Schug M., Schumann A., Wilhelm C., Freis E., Ickstadt K., Rahnenfuhrer J., Baumbach J.I., Sickmann A., Hengstler J.G. Role of thioredoxin reductase 1 and thioredoxin interacting protein in prognosis of breast cancer. Breast Cancer Res 2010, 12:R44.
22. Cunnea P., Fernandes A.P., Capitanio A., Eken S., Spyrou G., Bjornstedt M. Increased expression of specific thioredoxin family proteins; a pilot immunohistochemical study on human hepatocellular carcinoma. Int. J. Immunopathol. Pharmacol. 2007, 20:17-24.
23. Lincoln D.T., Ali Emadi E.M., Tonissen K.F., Clarke F.M. The thioredoxin-thioredoxin reductase system: over-expression in human cancer. Anticancer Res. 2003, 23:2425-2433.
24. Nguyen P., Awwad R.T., Smart D.D., Spitz D.R., Gius D. Thioredoxin reductase as a novel molecular target for cancer therapy. Cancer Lett. 2006, 236:164-174.
25. Kromer A., Moosmann B. Statin-induced liver injury involves cross-talk between cholesterol and selenoprotein biosynthetic pathways. Mol. Pharmacol. 2009, 75:1421-1429.
26. Moosmann B., Behl C. Selenoprotein synthesis and side-effects of statins. Lancet 2004, 363:892-894.
27. Barnes K.M., Evenson J.K., Raines A.M., Sunde R.A. Transcript analysis of the selenoproteome indicates that dietary selenium requirements of rats based on selenium-regulated selenoprotein mRNA levels are uniformly less than those based on glutathione peroxidase activity. J. Nutr. 2009, 139:199-206.
28. Carlson B.A., Xu X.M., Gladyshev V.N., Hatfield D.L. Selective rescue of selenoprotein expression in mice lacking a highly specialized methyl group in selenocysteine tRNA. J. Biol. Chem. 2005, 280:5542-5548.
29. Furman C., Rundlof A.K., Larigauderie G., Jaye M., Bricca G., Copin C., Kandoussi A.M., Fruchart J.C., Arner E.S., Rouis M. Thioredoxin reductase 1 is upregulated in atherosclerotic plaques: specific induction of the promoter in human macrophages by oxidized low-density lipoproteins. Free Radic. Biol. Med. 2004, 37:71-85.